TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05818670
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: long term follow up
Study: NCT00562809
Drug: IRBESARTAN
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150/12.5 mg tablets one or two tablets orally per day
Study: NCT04493164
Drug: Ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04493164
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00538642
Drug: ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
Study: NCT02656472
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXA Loading dose: 31 mg/kg diluted to 2 ml/kg Normal saline (NS) -in syringe
Study: NCT02656472
Drug: Epsilon Aminocaproic Acid
Normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS
Study: NCT03551522
Drug: Seladelpar
Normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, 20 mg, or 50 mg
Study: NCT03809624
Drug: INBRX-105 - PDL1x41BB antibody
Normalized name: INBRX-101
DrugBank: INBRX-101 (DB18384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
Study: NCT03809624
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Study: NCT03277196
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granules for oral administration.
Study: NCT03702725
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.
Study: NCT03702725
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.
Study: NCT03702725
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
Study: NCT01365221
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
Study: NCT01365221
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
Study: NCT00486486
Drug: Drug: bimatoprost/timolol fixed combination AM
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month chronic dosing in the morning
Study: NCT00486486
Drug: Bimatoprost/timolol fixed combination dosed PM
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
Study: NCT00030082
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00659295
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
Study: NCT02451956
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
Study: NCT03217162
Drug: mechanical ventilation (MV)
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mechanical ventilation (MV) is given to the infant with ARDS
Study: NCT00937235
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg tablets, orally, twice daily x 12 weeks
Study: NCT00861341
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81 mg
Study: NCT00861341
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg Pioglitazone x1
Study: NCT00210834
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03047538
Drug: Atorvastatin, Amlodipine, Perindopril
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To compare free and fixed combination of atorvastatin, perindopril, amlodipine
Study: NCT02221089
Drug: Escherichia coli Endotoxin
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
Study: NCT02609581
Drug: Sublingual Immunotherapy with tablets (mites)
Normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
Study: NCT01028352
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with open-label duloxetine:~* 30 mg daily x 7 days, then~* 60 mg daily x 3 weeks, then~* If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~* If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~* After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician.
Study: NCT02427165
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a beta-2 receptor agonist
Study: NCT00006122
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006122
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006122
Drug: gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00006122
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006122
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01121289
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study: NCT03389243
Drug: Metamizol
Normalized name: Metamizol
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
Study: NCT03389243
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
Study: NCT03389243
Drug: paracetamol and metamizole
Normalized name: codeine and paracetamol
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
Study: NCT02293109
Drug: carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02293109
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02293109
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02293109
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02293109
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02462161
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
Study: NCT00507715
Drug: Plantago ovata husk
Normalized name: Plantago ovata seed
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
Study: NCT03263091
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral tablets
Study: NCT00312013
Drug: Nadroparin
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
Study: NCT00135421
Drug: Pexacerfont
Normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets \& Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
Study: NCT00135421
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets \& Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
Study: NCT01719757
Drug: Oxycodone/Naloxone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twice daily
Study: NCT02626338
Drug: Crenolanib
Normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02626338
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02626338
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02626338
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02626338
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02626338
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02626338
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00876031
Drug: trofosfamide, idarubicin, etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral maintenance therapy for 6 months
Study: NCT03815890
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 courses 240 mg flat dose
Study: NCT03815890
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single dose ipilimumab (1mg/kg) at day 1
Study: NCT03815890
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: two courses ipilimumab (1mg/kg) at day 1 and 21
Study: NCT04101812
Drug: PD-1
Normalized name: NPD-1
DrugBank: PD-168393 (DB07662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
Study: NCT01896232
Drug: Etelcalcetide
Normalized name: Etelcalcetide
DrugBank: Etelcalcetide (DB12865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
Study: NCT01896232
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
Study: NCT00044447
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03732547
Drug: PD-1 mAb
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
Study: NCT03732547
Drug: PolyIC
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
Study: NCT02443402
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) \< 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
Study: NCT01334697
Drug: recombinant human cardiotrophin-1
Normalized name: antihemophilic factor, human recombinant 1 UNT [Recombinate]
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous administration
Study: NCT03115424
Drug: Saxenda
Normalized name: Saxenda
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
Study: NCT02443402
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate \>2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~* If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~* If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~* If fasting and pre-dinner BG is \> 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~* If fasting and pre-dinner BG is \< 100 mg/dL in the absence of hypoglycemia: stop glargine
Study: NCT02443402
Drug: Supplemental insulin (Insulin lispro)
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro
Study: NCT02443402
Drug: Supplemental insulin (Insulin aspart)
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG \> 400 mg/dL; 7-9 units of insulin aspart
Study: NCT00321516
Drug: aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
Study: NCT01495988
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
Study: NCT01495988
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
Study: NCT01495988
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
Study: NCT01737814
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02083276
Drug: Pivmecillinamhydrochlorid
DrugBank: Pivmecillinam (DB01605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO 400 mg x3 for 7 days
Study: NCT00277537
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 320mg BD 12 weeks followed by 40 weeks open label
Study: NCT00003417
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02314806
Drug: Irrigation with Normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The surgical bed is irrigated with normal saline
Study: NCT00483002
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As prescribed by physician in usual clinical practice.
Study: NCT00115895
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
Study: NCT03033199
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40 mg per day, 4 consecutive days
Study: NCT01181674
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sc injection
Study: NCT01181674
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral administration
Study: NCT01181674
Drug: acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT01707381
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical ophthalmic solution
Study: NCT04721873
Drug: Phentermine-Topiramate
Normalized name: phentermine-topiramate
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to either once-daily, oral phentermine-topiramate 15-92mg or placebo, in a 1:1 fashion, for 22 weeks, with clinic visits with an obesity medicine specialist, for intensive counseling for diet and lifestyle intervention. All patients will be dose-titrated within the first 4 weeks, starting at phentermine-topiramate 3.75-23mg, or placebo. Dose titration will be performed as follows 3.75-23mg x 1 week --\> 7.5-46mg x 1 week --\> 11.25-69mg x 1 week --\> 15-92mg. Patients who experience side effects would undergo slower titration, and dose would be down-titrated and capped at highest tolerated dose.
Study: NCT04721353
Drug: Prazosin Hydrochloride
Normalized name: Prazosin Hydrochloride
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prazosin hydrochloride oral 1-25 mg/day
Study: NCT00864760
Drug: Gabapentin 800 mg tablets, single dose (1 tablet)
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions